Search

everythinglearnresearchcommunity

for

Search:↓

Methotrexate and vitamin D3 are potentially more effective and safer than triamcinolone for treating localized alopecia areata.

There are many treatments for common hair loss, but more trials are needed to decide which are best.

The demineralized bone matrix scaffold is better for cell attachment than the mineralized bone allograft.

Eculizumab helps reduce blood transfusions and stabilize hemoglobin but increases infection risk and is expensive.

Dengue virus can infect human hair follicle cells and may cause hair loss.

Foxp3 is crucial for regulatory T cell function, and targeting these cells may help treat immune disorders.

NF-κB is crucial for zebrafish heart repair, affecting heart cell growth and repair processes.

Both vitiligo and alopecia areata involve an immune response triggered by stress and specific genes, with treatments targeting this pathway showing potential.

CRAC channels are crucial for the development and function of specialized immune cells, preventing severe inflammation and autoimmune diseases.

Graphene oxide and indole-3-acetic acid together inhibit root growth in Brassica napus L. by affecting multiple plant hormone pathways.

Blocking IL-12/IL-23 does not help with hair loss in alopecia areata for mice or humans.

CD201+ fascia progenitors are essential for wound healing and could be targeted for treating skin conditions.

The effects of estrogen on human scalp hair growth are unclear and need more research.

Benzothiazepines like diltiazem reduce anxiety in mice by making neurosteroids.

Hair loss causes emotional distress, leading to high spending on treatments, with Minoxidil and Propecia being common but having side effects.

The decision tree can predict drug absorption issues with good accuracy but needs more validation and adjustments for other factors.

Anti-IL-12/IL-23 antibody therapy effectively treats psoriasiform skin lesions in IBD patients.

Cancer patients treated with immune checkpoint inhibitors may develop alopecia, but some hair regrowth is possible with treatment.

Anti-TNF therapy can cause a unique type of hair loss that may get better with topical treatments without stopping the therapy.

There are still challenges in diagnosing and treating chronic skin diseases, but there is hope for future improvements.

A blood pressure drug, diltiazem, may also help treat influenza.

JAK inhibitors show promise for treating skin and hair disorders but need more research on long-term safety and effectiveness.

Tofacitinib citrate is effective for moderate-to-severe chronic plaque psoriasis but has safety concerns at higher doses.

People with lichen planus are more likely to have dyslipidemia, especially higher triglyceride levels.

The European Society of Cutaneous Lupus Erythematosus created a questionnaire to standardize patient assessment and improve care for cutaneous lupus.

Shrinking of oil glands in the skin is a key sign of hair loss linked to TNF inhibitor drugs and may improve if the treatment is stopped.

Stopping adalimumab and starting methotrexate with topical treatments improved the woman's scalp psoriasis and hair regrew.

The new chemotherapy combination of WP 631 and Epothilone B shows enhanced effectiveness against ovarian cancer but requires more research on its safety.

Some drugs, especially biologics, can cause skin reactions that look like other skin diseases, and stopping the drug usually helps clear up these reactions.

The conference highlighted new dermatological treatments and emphasized early intervention and addressing conditions lacking evidence-based treatments.